Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jukka Westermarck

Showing results (61-70 of 97) with videos related to

Pageof 10
Sort By:
The Journal of Biological Chemistry|January 9, 2008
c-Jun supports ribosomal RNA processing and nucleolar localization of RNA helicase DDX21Tim H Holmström, Antoine Mialon, Marko Kallio, et al.
Oncogene|June 5, 2025
NRF2-mediated persistent adaptation of oesophageal adenocarcinoma cells to HER2 inhibitionWei Zhang, Jiaqing Lang, Sorayut Chattrakarn, et al.
Cell Reports|June 8, 2023
Endogenous PP2A inhibitor CIP2A degradation by chaperone-mediated autophagy contributes to the antitumor effect of mitochondrial complex I inhibitionRiccardo Cazzoli, Francesco Romeo, Isabella Pallavicini, et al.
Cancer Research|March 19, 2009
PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant gliomaPietri Puustinen, Melissa R Junttila, Sari Vanhatupa, et al.
Iscience|March 15, 2020
CIP2A Constrains Th17 Differentiation by Modulating STAT3 SignalingMohd Moin Khan, Ubaid Ullah, Meraj H Khan, et al.
EMBO Molecular Medicine|June 17, 2024
DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancerMajid Momeny, Mari Tienhaara, Mukund Sharma, et al.
Brain Communications|September 21, 2020
Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastomaJoni Merisaari, Oxana V Denisova, Milena Doroszko, et al.
Oral Oncology|March 4, 2022
Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinomaJohannes Routila, Xi Qiao, Jere Weltner, et al.
Oncotarget|May 13, 2015
CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populationsAnchit Khanna, Jayant K Rane, Kati K Kivinummi, et al.
Nature Communications|August 5, 2016
Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcriptionRiina Kaukonen, Anja Mai, Maria Georgiadou, et al.
Pageof 10

Showing results (61-70 of 97) with videos related to

Sort By:
Pageof 10
The Journal of Biological Chemistry|January 9, 2008
c-Jun supports ribosomal RNA processing and nucleolar localization of RNA helicase DDX21Tim H Holmström, Antoine Mialon, Marko Kallio, et al.
Oncogene|June 5, 2025
NRF2-mediated persistent adaptation of oesophageal adenocarcinoma cells to HER2 inhibitionWei Zhang, Jiaqing Lang, Sorayut Chattrakarn, et al.
Cell Reports|June 8, 2023
Endogenous PP2A inhibitor CIP2A degradation by chaperone-mediated autophagy contributes to the antitumor effect of mitochondrial complex I inhibitionRiccardo Cazzoli, Francesco Romeo, Isabella Pallavicini, et al.
Cancer Research|March 19, 2009
PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant gliomaPietri Puustinen, Melissa R Junttila, Sari Vanhatupa, et al.
Iscience|March 15, 2020
CIP2A Constrains Th17 Differentiation by Modulating STAT3 SignalingMohd Moin Khan, Ubaid Ullah, Meraj H Khan, et al.
EMBO Molecular Medicine|June 17, 2024
DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancerMajid Momeny, Mari Tienhaara, Mukund Sharma, et al.
Brain Communications|September 21, 2020
Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastomaJoni Merisaari, Oxana V Denisova, Milena Doroszko, et al.
Oral Oncology|March 4, 2022
Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinomaJohannes Routila, Xi Qiao, Jere Weltner, et al.
Oncotarget|May 13, 2015
CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populationsAnchit Khanna, Jayant K Rane, Kati K Kivinummi, et al.
Nature Communications|August 5, 2016
Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcriptionRiina Kaukonen, Anja Mai, Maria Georgiadou, et al.
Pageof 10